Welcome to CDC Stacks | Updated Recommendations for use of Haemophilus influenzae Type b (Hib) Vaccine: Reinstatement of the Booster Dose at Ages 12-15 Months - 7439 | Guidelines and Recommendations
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Updated Recommendations for use of Haemophilus influenzae Type b (Hib) Vaccine: Reinstatement of the Booster Dose at Ages 12-15 Months
  • Published Date:
    June 26, 2009
  • Status:
    retired
  • Source:
    MMWR. Morbidity and mortality weekly report. 2009; 58(24):673-4.
Filetype[HTML - ]
View this content


This is an HTML document so it cannot be previewed.
To open, click the "View" button.
Details:
  • Corporate Authors:
    United States. Advisory Committee on Immunization Practices. ; American Academy of Family Physicians. ; American Academy of Pediatrics.
  • Keywords:
  • Description:
    On December 13, 2007, certain lots of Haemophilus influenzae type b (Hib) vaccine marketed as PedvaxHIB (monovalent Hib vaccine) and Comvax (Hib-HepB vaccine), and manufactured by Merck & Co., Inc., were recalled voluntarily, and the company temporarily suspended production of these vaccines. To conserve the limited supply of Hib-containing vaccines, CDC, in consultation with the Advisory Committee on Immunization Practices (ACIP), the American Academy of Family Physicians (AAFP), and the American Academy of Pediatrics (AAP), on December 18, 2007, recommended that vaccination providers temporarily defer the routine Hib vaccine booster dose administered to most healthy children at age 12-15 months

  • Collection(s):
    Guidelines and Recommendations
  • Supporting Files:
    No Additional Files
No Related Documents.
You May Also Like:
  1. Licensure of a Haemophilus influenzae Type b (Hib) Vaccine (Hiberix) and Updated Recommendations for Use of Hib Vaccine; MMWR 2009; 58 (36):1008-1009.
    Published:
    September 18, 2009
    Source:
    MMWR. Morbidity and mortality weekly report. 2009; 58(36):1008-9.
    Description:
    On August 19, 2009, the Food and Drug Administration (FDA) licensed Hiberix (GlaxoSmithKline Biologicals, Rixensart, Belgium), a Haemophilus influenzae type b (Hib) conjugate vaccine composed of H. influenzae type b capsular polysaccharide (polyribos...
    Status:
    current
    File Type:
    Filetype[HTML]
  2. Manual for the surveillance of vaccine-preventable diseases. Chapter 2: Haemophilus influenzae type b (Hib)
    Personal Author:
    Briere, Elizabeth C.; Wang, Xin;
    Corporate Author:
    National Center for Immunization and Respiratory Diseases (U.S.)
    Published:
    Feb 2015
    Series:
    Manual for the surveillance of vaccine-preventable diseases ; chapter 2
    Description:
    Chapter 2 of: Manual for the surveillance of vaccine-preventable diseases. 2015. : Haemophilus influenzae invasive disease is caused by the bacterium Haemophilus influenzae. H. influenzae may be either encapsulated (typeable) or unencapsulated (nonty...
    File Type:
    Filetype[PDF - 488.01 KB]
  3. Haemophilus influenzae Type b Disease and Vaccine Booster Dose Deferral, United States, 1998–2009
    Personal Author:
    Briere, Elizabeth C.; Jackson, Michael; Shah, Shetul G.; Cohn, Amanda C.; Anderson, Raydel D.; MacNeil, Jessica R.; Coronado, Fatima M.; Mayer, Leonard W.; Clark, Thomas A.; Messonnier, Nancy E.;
    Published:
    Aug 06 2012
    Source:
    Pediatrics. 130(3):414-420.
    Description:
    BACKGROUND : Since the introduction of effective vaccines, the incidence of invasive Haemophilus influenzae type b (Hib) disease among children <5 years of age has decreased by 99% in the United States. In response to a limited vaccine supply that...
    File Type:
    Filetype[PDF - 319.97 KB]
  4. SUPPLEMENTAL MAP 1. Countries with Haemophilus influenzae type b (Hib) vaccine in the national immunization program or planned introductions in 2016. Supplementary material for: Status of new vaccine introduction -- worldwide, September 2016
    Personal Author:
    Loharikar, Anagha; Dumolard, Laure; Chu, Susan Y.; Hyde, Terri B.; Goodman, Tracey; Mantel, Carsten;
    Published:
    October 21, 2016
    Source:
    Loharikar A, Dumolard L, Chu S, Hyde T, Goodman T, Mantel C. Status of New Vaccine Introduction – Worldwide, September 2016. MMWR Morb Mortal Wkly Rep 2016;65(41):1136–1140
    Series:
    MMWR. Morbidity and mortality weekly report ; v. 65, no. 41, p. 1136–1140
    File Type:
    Filetype[PDF - 168.66 KB]
  5. Conjugate vaccines and the carriage of Haemophilus influenzae type b.
    Personal Author:
    Barbour, M. L.
    Published:
    1996 Jul-Sep
    Source:
    Emerg Infect Dis. 2(3):176-182.
    Description:
    Pharyngeal carriage of Haemophilus influenzae type b (Hib) is important in the transmission of Hib organisms, the pathogenesis of Hib disease, and the development of immunity to the bacterium. The remarkable success of current vaccination programs ag...
    File Type:
    Filetype[PDF - 37.08 KB]